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can also be induced as a result of persistent damage and inﬂammation.
There are then two subsequent outcome possibilities with active EMT:
severe and even complete organ ﬁbrosis and secondarily association
with malignancy; both of these processes may be relevant to COPD pa-
thology and natural history. Lung cancer evolves as a result of a series of
mutational events in epithelial cells that have been studied in detail by
numerous investigators. However, it is not only epithelial malignantLung cancer and chronic obstructive pulmonary disease (COPD)
cells develop i.e. the tumor microenvironment. We suggest that EMT-
Type-3 provides a pro-cancer stroma that both stimulates epithelialcommonly coexist in smokers, and the presence of COPD increases the
risk of developing lung cancer by 4–5 folds, evenwhen the smoking his-
tory is controlled for (Sohal et al., 2014a; Sohal et al., 2013). Lung cancer
may consist of small cell carcinoma and non-small cell carcinomas
encompassing squamous cell carcinoma, adenocarcinoma and large
cell carcinoma. In a recent very comprehensive study by Huang and
colleagues published in EBioMedicine, provided compelling evidence
suggesting strong association between smoking, COPD and small cell
lung cancer (SCLC) (Huang et al., 2015). This publication is a very timely
reminder highlighting the importance of this lethal association between
COPD/lung cancer and warrants further experimental studies exploring
this link not only in SCLC but lung cancer in general. Unfortunately, the
research effort directed into this has been disproportionately weak
compared to its clinical and scientiﬁc importance, and indeed COPD it-
self is the least researched of all common chronic conditions compared
to its social importance.
Lung cancer and COPD share a common etiology i.e. mainly tobacco
smoking. This implies that mechanisms speciﬁc to COPD may be in-
volved in the development of lung cancer (Sohal et al., 2013; Yang
et al., 2011). Potential shared biological mechanisms in COPD and lung
cancer include: chronic inﬂammation, matrix degradation, cell prolifer-
ation and anti-apoptosis, abnormal wound repair and angiogenesis, but
perhaps especially the process of epithelial mesenchymal transition
(EMT), a highly plastic process in which epithelial cells change into a
mesenchymal phenotype (Yang et al., 2011). There is much support
for a major role for EMT in the pathogenesis of epithelial cancers
(Garber, 2008). It is clear that several of the key pathways driving
EMT, which is designed teleologically for the highly controlled process
of embryogenesis, are also aberrantly activated in cancer (Sohal et al.,om.2015.09.031.
. This is an open access article undertransformation that matters, but also the environment in which these
cancer cell transformation, in addition to the genetic changes induced
by cigarette smoke, but then allows these cells to thrive, invade and
metastasise (Mahmood et al., 2015). In a separate twist to this complex
story, the epithelial cancer itself also directly uses EMT mechanisms to
spread and metastasise.
It is of interest and relevance in this context that over 90% of human
cancer arises in epithelia (e.g., breast, colon, stomach, liver, prostate,
ovary/fallopian tube and bladder), and the involvement of EMT in all
of these may be a central paradigm (Garber, 2008). It is pertinent that
up to 70% of lung cancer occurs in the context of mild-to-moderate
(not severe) COPD (Barnes andAdcock, 2011), and COPD-related cancer
may well be just another example of this core principle of unstable
epithelium in the context of tissue inﬂammation and/or chronic
stimulation.
Recently, we reported (Sohal et al., 2014b) in a randomized con-
trolled trial that inhaled corticosteroid ﬂuticasone propionate given
over six months suppressed EMT-related changes in large airways of
COPD patients. This trial showed marked reduction in EMT related
changes in the active inhaled corticosteroids (ICS) compared to placebo
(Sohal et al., 2014b). This is the ﬁrst study reporting anti-EMT effects of
inhaled corticosteroids in COPD, where of course they are widely used
as putative “anti-inﬂammatory” agent, although that mode of operation
is far from convincing. In human epidemiological studies it is strongly
suggested that patients on inhaled corticosteroids, albeit only at high
doses (as used in our study), are associated with an appreciable (50%)
reduction in the risk of lung cancer (Parimon et al., 2007). However,
the TORCH study (Calverley et al., 2007) of ICS in severe COPD failed
to show this effect, but it was not powered to pick this up, and was a
study on severe rather than mild to moderate COPD where lung cancer
particularly occurs (Barnes and Adcock, 2011).
We suggest that EMTmight be the process bywhich this effect of ICS
occurs. If this is true, it has huge implications for therapeutic and publicthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
1579S.S. Sohal / EBioMedicine 2 (2015) 1578–1579health policy, since it is strongly suggested in literature that patients on
ICS are associated with a decreased risk for lung cancer (Parimon et al.,
2007). It is suggested that statins may also have similar effects on EMT
in COPD, since lung cancer risk decreases in COPD patients who are on
statins (Sohal et al., 2014a; Sohal et al., 2013), this warrants further
studies. There is an essential need for both in vivo and in vitro human
studies to understand the mechanistic link between COPD and airway
cancer and how ICS and the other drugs may affect it. Only by under-
standing what is happening and the mechanism involved, will new
therapeutic possibilities emerge.
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